Literature DB >> 11884455

The Pmed1 gene promoter of human Fc gamma RIIIA can function as a NK/T cell-specific restriction element, which involves binding of Sp1 transcription factor.

Frank Heusohn1, Gundula Wirries, Reinhold E Schmidt, J Engelbert Gessner.   

Abstract

The low-affinity receptor for IgG (human FcgammaRIIIA) is selectively expressed by a subset of T lymphocytes, NK cells, and macrophages. To understand the mechanisms underlying this pattern of cell type-specific expression, we initially identified alternative promoters, Pmed1/2 and Pprox, in the 5' end of the FcgammaRIIIA gene. In this study, we focused on the Pmed1 promoter and demonstrated this 93-bp region to be highly specific in governing restriction to NK/T cell lines. This property of Pmed1 is context independent and can extend to a disparate promoter. Deletion analysis defined a contribution of two separate elements located to the 5' 21-bp (-942/-922) and 3' 72-bp (-921/-850) regions of Pmed1 in conferring NK/T cell specificity. The 5' part of Pmed1 contains binding sites for Sp1 and NK element-recognizing factors and substitution mapping studies revealed a critical requirement of the Sp1-I site. The importance of Sp1 protein to regulate maximal Pmed1 promoter activity was further established by EMSAs and cotransfection experiments in Sp1-null Drosophila SL2 cells. Our data suggest that Sp1 can contribute, in part, to NK/T cell restriction and further indicate that the FcgammaRIIIA Pmed1 sequence might be useful to direct the NK/T cell-specific expression of heterologous genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884455     DOI: 10.4049/jimmunol.168.6.2857

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  1 in total

1.  Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.

Authors:  Aaron R Victor; Christoph Weigel; Steven D Scoville; Wing Keung Chan; Kelsey Chatman; Mary M Nemer; Charlene Mao; Karen A Young; Jianying Zhang; Jianhua Yu; Aharon G Freud; Christopher C Oakes; Michael A Caligiuri
Journal:  J Immunol       Date:  2017-12-11       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.